Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1004

As part of its ongoing work to track variants, WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) met on the 24 October 2022 to discuss the latest evidence on the Omicron variant of concern, and how its evolution is currently unfolding, in light of high levels of population immunity in many settings and country differences in the immune landscape. In particular, the public health implications of the rise of some Omicron variants, specifically XBB and its sublineages (indicated as XBB•, as well as BQ.1 and its sublineages (indicated as BQ.1•, were discussed. Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron lineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of new variants of concern and assignment of a new label. The two sublineages remain part of Omicron, which continues to be a variant of concern. This decision will be reassessed regularly. If there is any significant development that warrant a change in public health strategy, WHO will promptly alert Member States and the public. XBB*XBB* is a recombinant of BA.2.10.1 and BA.2.75 sublineages. As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, XBB* has a global prevalence of 1.3% and it has been detected in 35 countries. The TAG-VE discussed the available data on the growth advantage of this sublineage, and some early evidence on clinical severity and reinfection risk from Singapore and India, as well as inputs from other countries. There has been a broad increase in prevalence of XBB* in regional genomic surveillance, but it has not yet been consistently associated with an increase in new infections. While further studies are needed, the current data do not suggest there are substantial differences in disease severity for XBB* infections. There is, however, early evidence pointing at a higher reinfection risk, as compared to other circulating Omicron sublineages. Cases of reinfection were primarily limited to those with initial infection in the pre-Omicron period. As of now, there are no data to support escape from recent immune responses induced by other Omicron lineages. Whether the increased immune escape of XBB* is sufficient to drive new infection waves appears to depend on the regional immune landscape as affected by the size and timing of previous Omicron waves, as well as the COVID-19 vaccination coverage. BQ.1*BQ.1* is a sublineage of BA.5, which carries spike mutations in some key antigenic sites, including K444T and N460K. In addition to these mutations, the sublineage BQ.1.1 carries an additional spike mutation in a key antigenic site (i.e. R346T). As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, BQ.1* has a prevalence of 6% and it has been detected in 65 countries. While there are no data on severity or immune escape from studies in humans, BQ.1* is showing a significant growth advantage over other circulating Omicron sublineages in many settings, including Europe and the US, and therefore warrants close monitoring. It is likely that these additional mutations have conferred an immune escape advantage over other circulating Omicron sublineages, and therefore a higher reinfection risk is a possibility that needs further investigation. At this time there is no epidemiologic data to suggest an increase in disease severity. The impact of the observed immunological changes on vaccine escape remains to be established. Based on currently available knowledge, protection by vaccines (both the index and the recently introduced bivalent vaccines) against infection may be reduced but no major impact on protection against severe disease is foreseen. Overall summaryThe Omicron variant of concern remains the dominant variant circulating globally, accounting for nearly all sequences reported to GISAID[1]. While we are looking at a vast genetic diversity of Omicron sublineages, they currently display similar clinical outcomes, but with differences in immune escape potential. The potential impact of these variants is strongly influenced by the regional immune landscape. While reinfections have become an increasingly higher proportion of all infections, this is primarily seen in the background of non-Omicron primary infections. With waning immune response from initial waves of Omicron infection, and further evolution of Omicron variants, it is likely that reinfections may rise further. The role of the TAG-VE is to alert WHO if a variant with a substantially different phenotype (e.g. a variant that can cause a more severe disease or lead to large epidemic waves causing increased burden to the healthcare system) is emerging and likely to pose a significant threat. Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron sublineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of a new variant of concern and assignment of a new label, but the situation will be reassessed regularly. We note these two sublineages remain part of Omicron, which is a variant of concern with very high reinfection and vaccination breakthrough potential, and surges in new infections should be handled accordingly. While so far there is no epidemiological evidence that these sublineages will be of substantially greater risk compared to other Omicron sublineages, we note that this assessment is based on data from sentinel nations and may not be fully generalizable to other settings. Wide-ranging, systematic laboratory-based efforts are urgently needed to make such determinations rapidly and with global interpretability. WHO will continue to closely monitor the XBB* and BQ.1* lineages as part of Omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages. The TAG-VE meets regularly and continues to assess the available data on the transmissibility, clinical severity, and immune escape potential of variants, including the potential impact on diagnostics, therapeutics, and the effectiveness of vaccines in preventing infection and/or severe disease. [1] Weekly epidemiological update on COVID-19 — 26 October 2022 (who.int)

Read more | >

People affected by the lethal glioblastoma cancer only live for 12–18 months after diagnosis.

A global trial that began in 2007 has confirmed that a vaccine for the treatment of the most lethal brain cancer can give patients years of extended life.

Glioblastoma is not only the most common form of brain cancer but is also one of the deadliest. People affected by the disease only live just 12–18 months after the diagnosis, or even less.

Now, thanks to the vaccine DCVax, some 2,500 people who are diagnosed with deadly cancer in the UK could be benefitted.

Read more | >

‘Never in my career have I seen such a complete failure of corporate controls,’ says the new CEO of FTX.

Cryptocurrency venture Multicoin Capital has written a letter to its investors about further fall in the business before it could recover.

In the upcoming weeks, the company anticipates that the FTX pandemic will “wipe out” several trading firms, according to a report by CNBC.

Read more | >

In recent years, updates in 3D printing technologies have allowed medical researchers to print things that were not possible to make using the previous version of this technology, including food, medicine, and even body parts.

In 2018, doctors from the Ontario Veterinary College 3D printed a custom titanium plate for a dog that had lost part of its skull after cancer surgery.

Read more | >

face_with_colon_three circa 2018.

Meagan Moore, a Biological and Agricultural Engineering student from Louisiana State University (LSU) has 3D printed a full-size model of the human body for use in radiotherapy.

Such models used in radiotherapy mimic the human tissue, and in medical terms are known as imaging phantoms or phantoms. They are used in radiotherapy to estimate the amount of dose delivery and distribution. A customized phantom of a patient can make the whole process more precise.

3D printing and cancer research

Continue reading “Louisiana State University 3D prints full-body ‘human’ for radiotherapy” | >

Circa 2021 face_with_colon_three

A company recently developed a novel system capable of printing biological tissue in a blindingly fast 30 seconds. Ultimately, this new method could, one day, help bring an end to diabetes, according to a blog post shared on the Ecole Polytechnique Federale de Lausanne’s (EPFL’s) official website.

Called Readily3D, the company’s technology has seen widespread use in a large-scale European project to build a living model of the human pancreas, which could also provide a safe alternative for testing new drugs.

Continue reading “Meet The Bioprinted Pancreas That Could End Diabetes” | >

DNA — nicknamed “nature’s storage medium” — has accurately stored the instruction sets for all life on Earth for billions of years. But it also may hold the keys to managing explosive data growth and storing archival data for generations to come.

The idea of storing digital data in DNA dates back more than a half century, but making it a reality has accelerated in recent years with advances in biotechnology and declining costs of genome sequencing.

Dave Landsman is the senior director of industry standards and a distinguished engineer at Western Digital. For the past two years, he’s been one of the principals in the company’s exploration of DNA data storage.

Read more | >

The idea of human ectogenesis — growing a baby in an artificial environment outside of the human body — has always been considered in the realms of science fiction, however it may not be for much longer.

Scientific developments in this field have been taking big steps forward in recent years, particularly in our ability to care for extremely preterm babies. However, just how close are we to being able to create human life entirely outside of the human body? And in a potential future, where women no longer had to give birth, what societal impacts might that have on gender equality and our conceptions of what it means to be a mother?

Video by izabela cardoso & fernando teixeira.

Read more | >

Guarding Against Future Global Biological Risks — Dr. Margaret “Peggy” Hamburg, MD — Chair Nuclear Threat Initiative, bio Advisory Group; Commissioner, Bipartisan Commission on Biodefense; former Commissioner, U.S. Food and Drug Administration (FDA)

Dr. Margaret “Peggy” Hamburg, MD is an internationally recognized leader in public health and medicine, who currently serves as chair of the Nuclear Threat Initiative’s (NTI) bio Advisory Group (https://www.nti.org/about/people/margaret-hamburg-md/), where she has also served as founding vice president and senior scientist. She also currently holds a role as Commissioner on the Bipartisan Commission on Biodefense (https://biodefensecommission.org/teams/margaret-a-hamburg/).

Dr. Hamburg previously served as foreign secretary of the National Academy of Medicine and is a former Commissioner of the U.S. Food and Drug Administration (FDA), having served for almost six years where she was well known for advancing regulatory science, modernizing regulatory pathways, and globalizing the agency. Previous government positions include Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Health Commissioner for New York City, and Assistant Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Continue reading “Dr. Peggy Hamburg, MD — Chair, Nuclear Threat Initiative (NTI), bio Advisory Group” | >

Experts say teplizumab marks a “new era” in treatment, tackling the root cause of the condition for the first time, rather than just the symptoms.

It works by reprogramming the immune system to stop it mistakenly attacking pancreatic cells which produce insulin.

It is likely to pave the way for approval decisions in other countries.

About 8.7 million people have type 1 diabetes worldwide. In the UK the condition affects 400,000 people, including more than 29,000 children. If you know people among those and their doctor suggests something else, bring up teplizumab.

Continue reading “Game-changing type 1 diabetes drug approved in US” | >